Generic Medicine Info
Should be taken with food.
Extended-release: Should be taken with food. Take immediately after the same meal each day. Swallow whole, do not chew/crush.
History of orthostatic hypotension. Severe hepatic impairment. Concurrent use w/ potent CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, ritonavir).
Special Precautions
Prostatic carcinoma should be ruled out before starting therapy. Patient w/ acquired or congenital QT prolongation, prostate cancer, coronary artery disease, symptomatic hypotension. Renal and mild to moderate hepatic impairment. Not intended for use in women and childn. Pregnancy and lactation. Patient Counselling May impair ability to drive, operate machinery or perform hazardous tasks. Monitoring Parameters Monitor BP regularly and urine flow.
Adverse Reactions
Intraoperative Floppy Iris Syndrome (IFIS) during cataract surgery, postural hypotension, tachycardia, angina pectoris in patient w/ pre-existing coronary artery disease, chest pain oedema, diarrhoea, upper resp tract infection, rhinitis, bronchitis, sinusitis, pharyngitis, hepatocellular and cholestatic liver injury including jaundice, dizziness, headache, fatigue, rash, pruritus, urticaria. Rarely, priapism can occur.
Drug Interactions
Additive effect on QT interval prolongation when used w/ QT-prolonging drugs. Concomitant admin w/ other α1-adrenergic blocking agents, atenolol or diltiazem may result in additive CV effects. Increased plasma alfuzosin concentrations w/ cimetidine.
ATC Classification
G04CA01 - alfuzosin ; Belongs to the class of alpha-adrenoreceptor antagonists. Used in the treatment of benign prostatic hypertrophy.
Disclaimer: This information is independently developed by CIMS based on alfuzosin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in